|
Contents: (Full text available in print edition.)
- Human Skin Equivalent, Apligraf® -- Cellular technology benefits wound repair
- Update on Sunscreens
- Current Approaches to the Management of Post Herpetic Neuralgia: Part 2 -- Non-Systemic
- Update on Drugs
Update on Sunscreens
Review by Dr. Robert Bissonnette, Vancouver |
|
Sunscreens have been in use for nearly
70 years. Originally designed to protect against sunburn, enable longer sun exposure and
promote tanning, sunscreens are now often promoted as a method for preventing skin cancer
and skin aging. Although there is experimental evidence in animals suggesting that used
adequately, sunscreens can prevent skin cancer, no prospective study has shown a decrease
in incidence of skin cancer in sunscreen users, and sunburn prophylaxis is currently the
only FDA-approved use of sunscreens. Preliminary studies suggest that new-generation
sunscreens could prevent photodermatoses like polymorphous light eruption.1 |
The regular and adequate use of sunscreens, avoiding the sun around
mid-day, staying in the shade, wearing hats with brims which can shade the head, face and
neck, and wearing clothes made from tightly woven fabrics, are all important factors that
could prevent the deleterious effects of sunlight.
Table 1 lists some sunscreen agents available with their
corresponding spectral photoprotection. Chemical agents protect by absorbing light,
whereas physical agents act mainly by reflecting and scattering light. The recent
development of micronized preparations of physical agents has improved the cosmetic
acceptability of physical sunscreens. We will review some key factors to consider when
selecting a sunscreen and will compare some commercially available sunscreens, including
new sunscreens made recently available in North America (Table 2).
Factors to consider when selecting a sunscreen
- UVB protection UVB (290-320nm) is
the most erythemogenic solar radiation reaching the surface of the earth. It is also a
potent skin carcinogen in animal studies. Sun Protection Factor (SPF) indicates
the degree of protection against UVB induced erythema. It is measured in the laboratory by
applying 2 mg/cm² of sunscreen to the skin of volunteers and irradiating with an
artificial light source. Studies have shown that people use an average of 0.5 to 1 mg/cm²
of sunscreen,4,5
and that the SPF may overestimate the actual protection against sunlight.6 The real protection against sun-induced erythema of a
self-applied SPF 15 sunscreen is thus lower than 15, probably not much more than half this
figure. By applying a sunscreen with a SPF of 30 or higher, most people should get a SPF
protection equivalent to at least 15. UVB also induces immunosuppression, which in animal
studies is not totally prevented by sunscreens.7,8 One consequence of high SPF sunscreens is that, by
preventing sunburn, some people may stay under the sun for long periods of time and thus
receive high total daily UVA exposures.
TABLE 1.
Protection wavebands of sunscreens2,3
Sunscreen |
Protection (nm) |
Chemical sunscreens |
|
Aminobenzoic acid and
derivatives |
|
|
PABA |
260-313 |
|
|
Lisadimate (Glyceryl PABA) |
264-315 |
|
|
Padimate O |
290-315 |
|
|
Roxadimate |
280-330 |
|
Anthranilates |
|
|
Menthyl anthranilate |
260-380 |
|
Benzophenones |
|
|
Dioxybenzone |
250-390 |
|
|
Oxybenzone |
270-350 |
|
|
Sulisobenzone (Eusolex 4360) |
260-375 |
|
Camphor derivatives |
|
|
Benzoate-4 methylbenzylidene camphor |
290-300 |
|
|
Mexoryl SX |
290-400 |
|
Cinnamates |
|
|
Octocrylene |
250-360 |
|
|
Octyl methoxycinnamate (Parsol MCX) |
290-320 |
|
Dibenzoylmethanes |
|
|
Avobenzone (Parsol 1789) |
320-400 |
|
Salicylates |
|
|
Homosalate |
295-315 |
|
|
Octyl salicylate |
280-320 |
|
|
Trolamine salicylate |
260-320 |
|
Others |
|
|
Phenylbenzimidazole |
290-340 |
Physical sunscreens |
|
|
Titanium dioxide |
290-700 |
|
|
Zinc oxide |
290-700 |
- UVA protection In animal models,
UVA (320-400 nm) has been implicated in skin sagging, skin cancer and immunosuppression.
UVA protection is now offered in most sunscreens, but unfortunately the labels usually
provide no indication of the level or wavelengths of UVA protection. Most UVA protecting
sunscreen agents only offer protection against short wave UVA (Table 1).
Relative protection against long wave UVA can be achieved by Avobenzone (Parsol 1789), and
physical agents. Mexoryl SX is a new sunscreen agent with maximal absorption in the
mid-UVA that also offers some UVB protection. Spectral protection, including UVA
protection, from micronized physical agents varies according to the size of the micronized
particles, with smaller particles providing more UVB and less UVA protection.9
TABLE 2.
Comparison of Some Sunscreens Available in North America
Product |
Sunscreen Agents |
Long wave UVA
protection |
Anthelios L Creama
SPF 60
Water resistant |
Benzoate-4
methylbenzylidene camphor
Mexoryl SX
Parsol 1789
Titanium dioxide |
5%
3.3%
3.5%
4.2% |
|
Yes. Parsol 1789,
Mexoryl SX and physical agents. |
Bain de Soleil 25 Lotionb
SPF 25
Waterproof 8 hours |
Titanium dioxide
Zinc oxide |
9.6%
1.5% |
|
Yes.
Physical agents. |
Durascreen Lotion 15
SPF 15
Waterproof 8 hours |
Benzophenone-3
Octyl methoxy cinnamate
Octyl salicylate
Titanium dioxide |
6%
7.5%
5%
1.6% |
|
Yes.
Physical agents. |
Ombrelle Extreme
SPF 30
Waterproof |
Benzophenone-3
Octyl methoxy cinnamate
Parsol 1789
Titanium dioxide |
6%
7.5%
2.5%
2% |
|
Yes. Parsol 1789
and physical agents. |
Pre Sun 30 Cream
SPF 30
|
Octyl methoxy cinnamate
Octyl salicylate
Oxybenzone
Parsol 1789 |
7.5%
5%
3%
3% |
|
Yes. Parsol 1789. |
a Could prevent polymorphous light eruption 1
b Contains no chemical sunscreen
- Children Sun exposure in the first 20
years of life is a strong determinant for the risk of skin cancer.10 Therefore sun protection throughout childhood and
teenage years is probably crucial to preventing such carcinogenesis. Direct sun exposure
should probably be minimized in children, and if they must spend periods of time outside
during the day, physical blockers such as clothing should be used; failing that,
sunscreens. Sprays and gels should be used with caution in young children as they can
irritate the skin and exacerbate atopic dermatitis. Sunscreens are not recommended for use
in children less than 6-12 months of age in order to discourage unnecessary sun exposure.
However, there is no strong reason to suggest that sunscreens are harmful in this age
group.
- Substantivity Substantivity is
the ability of a sunscreen to resist its removal by physical means such as sweating or
contact with water. If the SPF of a sunscreen stays unchanged after 40 minutes of contact
with water, it is said to be water resistant, whereas if it stays unchanged for
80 minutes or more, it is said to be waterproof. Thus a person staying outside in
a pool for six hours may wish to reapply a waterproof sunscreen at least four times to
ensure that the SPF remains unchanged. Some manufacturers state the actual time their
product remains waterproof, and products which are waterproof for six hours or more should
be used if prolonged exposure to water or prolonged sweating is anticipated.
- Allergic potential The prevalence
of allergic reactions to sunscreens is low and most reactions reported by patients are of
the irritant type. PABA and its derivatives, benzophenone and fragrances are among the
most allergenic ingredients in sunscreens, explaining why many commercial products no
longer contain PABA. Physical sunscreen agents do not cause allergic contact dermatitis.
- Photodegradation Certain
sunscreen agents like avobenzone (Parsol 1789) have been shown to isomerize and lose part
of their sun protection properties when exposed to light, whereas others like the newer
agent Mexoryl-SX are especially photostable.11
In vitro studies have shown that certain sunscreen formulations can lose more than half
their SPF value after one hour of artificial light exposure, suggesting that
photodegradation is an important factor to consider when evaluating sunscreens.12 In vivo studies are needed
comparing the photostability of sunscreens to both UVA and UVB.
Return to
Contents
References
- Moyal D, Binet O. Polymorphous light eruption: Its reproduction and
prevention by sunscreens. In: Lowe NJ, Shaath NA, Pathak MA, eds. Sunscreens development,
evaluation, and regulatory aspects. New York: Marcel Dekker, 1997: 611-617.
- Drug information for the health care professional. USP DI. Taunton:
Rand McNally, 1997: 2713-2729.
- Shaath NA. Evolution of modern sunscreen chemicals. In: Lowe NJ,
Shaath NA, Pathak MA, eds. Sunscreens development, evaluation, and regulatory aspects.New
York: Marcel Dekker, 1997: 3 33 .
- Stender IM, Andersen JL, Wulf HC. Sun exposure and sunscreen use
among sunbathers in Denmark. Acta Dermato-Venereologica 1996; 76: 31-3.
- Bech-Tomsen N, Wulf HC. Sunbathers application of sunscreen is
probably inadequate to obtain the sun protection factor assigned to the preparation. Photodermatol
Photoimmunol Photomed 1992/1993; 9: 242-244.
- Sayre RM, Kollias N, Ley RD et al. Changing the risk spectrum of
injury and the performance of sunscreen products throughout the day. Photodermatol
Photoimmunol Photomed 1994; 10: 148-153.
- Wolf P, Yarosh DB, Kripke ML. Effects of sunscreens and a DNA
excision repair enzyme on ultraviolet radiation-induced inflammation, immune suppression,
and cyclobutane pyrimidine dimer formation in mice. J Invest Dermatol 1993; 101:
523-527.
- Walker SL, Young AR. Sunscreens offer the same UVB protection
factors for inflammation and immunosuppression in the mouse. J Invest Dermatol
1997; 108: 133-138.
- Anderson MW, Hewitt JP, Spruce SR. Broad-spectrum physical
sunscreens: Titanium dioxide and zinc oxide. In: Lowe NJ, Shaath NA, Pathak MA, eds.
Sunscreens development, evaluation, and regulatory aspects. New York: Marcel Dekker, 1997:
353-397.
- Gallagher RP, Hill GB, Bajdik CD et al. Sunlight exposure,
pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma. Arch
Dermatol 1995; 131: 157-163.
- Deflandre A, Lang G. Photostability assessment of sunscreens.
Benzylidene camphor and bibenzoylmethane derivatives. Int J Cosmetic Sci 1988;
10: 53-62.
- Diffey BL, Stokes RP, Forestier S. et al. Suncare product
photostability: a key parameter for a more realistic in vitro efficacy evaluation. Eur
J Dermatol 1997; 7: 226-228.
Return to
Contents
Class |
Name/Company |
Approval Dates and Comments |
Anti-HIV |
Delavirdine
Rescriptor®
Pharmacia & Upjohn |
Approved by the FDA April 7, 1997 as an added potency
enhancement agent of HIV drug cocktails. It is a nonnucleoside reverse transcriptase
inhibitor, which is not as powerful as protease inhibitors. Skin reaction is the main
side effect of delavirdine. |
Skin Substitute |
Human skin equivalent
Apligraf®
Novartis |
Approved in Canada April 1997 for use in healing venous leg
ulcers. See article on page one of this issue. |
Return to
Contents |
|